Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03670043
Other study ID # 1005965
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 19, 2019
Est. completion date August 15, 2021

Study information

Verified date September 2021
Source West Side Institute for Science and Education
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall goal is to explore the hypothesis that prebiotic fiber Psyllium will ameliorate diarrhea in African American men (AAM) with Type2 Diabetes Mellitus (T2D).


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date August 15, 2021
Est. primary completion date October 15, 2020
Accepts healthy volunteers No
Gender Male
Age group 20 Years to 70 Years
Eligibility Inclusion criteria 1. Male (M) 2. African American (AA) race 3. Age 20-70 years 4. BMI 28-59 kg/m2 5. T2D 6. A1c 6.5 - 8.9% 7. eGFR =/> 30 8. Drug-naïve or use Glipizide or newly started on Metformin (within 2 weeks). Exclusion criteria 1. Chronic kidney disease stage 3b, 4 and 5 (eGFR < 30) 2. Insulin use 3. Oral steroids use (inhalers and creams are allowed) 4. Antibiotic use within the last month 5. Artificial heart valves 6. Hospitalization for chronic condition within 6 months prior to the study 7. History, manifestations or medications of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, psychiatric/ psychological disorders, or social circumstances which in the opinion of the investigator would be expected to interfere with the study or increase risk to the subject. 8. Use of other antidiabetic drugs (except glipizide and metformin). 9. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Additional Exclusion criteria for subjects who previously used Metformin: 1. Previous severe allergic reaction to metformin hydrochloride, such as angioedema. 2. Previous Metformin intolerance causing significant diarrhea or GI-upset. Would not exclude participants who had history of mild diarrhea with metformin use. 3. Previous side effects that the subject feels were related to Metformin and the subject is not interested to re-try metformin.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Psyllium powder
To evaluate whether Psyllium will alleviate diarrhea
Metformin Extended Release Oral Tablet
Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin

Locations

Country Name City State
United States Jesse Brown VA Medical Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
West Side Institute for Science and Education

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire This scale is based on symptoms that frequently occur in IBS cases, examines abdominal discomfort status, stool properties, and defecation feelings. The scale includes a total of 11 items, with 6 possible grades for each item that range from 0 points (never having this symptom) to 5 points (the symptom is always present). The total score is the sum of the scores for each item. The Total score is used. No "subscale" is used. Total range is minimum=0, maximum=55. The higher values represent a worse outcome. 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Withdrawn NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A